S2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease
Send us a text Donna Cryer joins the Surfers to discuss the importance of identity in lifestyle modification, after which our sponsors from Echosens present LIVErHEALTHY, a program that combines non-invasive testing, technology-enabled behavior support and a food and nutrition element. Over the past two weeks, we have discussed the idea that diagnostic development in Fatty Liver Disease are progressing faster than medication. This episode looks at the issue of non-pharmacologic therapy ...
4 Mars 20211h 5min
S2-E8.3 - Previewing NASH-TAG 2021: Two intriguing side conversations
Send us a text This conversation integrates two significant side conversations during the review of the NASH-TAG 2021 agenda, one about creativity and intellectual ferment and the other about what we can learn from COVID-19 about how to motivate patients. While reviewing the NASH-TAG 2021 agenda, the group digressed several times. This conversation incorporates the two most interesting. In the first, Stephen Harrison discusses how this meeting design drives creativity and intellectual ferment...
27 Feb 202117min
S2-E8.2 - Previewing NASH-TAG 2021: Day Two
Send us a text Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell, and Roger Green the issues that each of them anticipates most eagerly. Stephen Harrison previews the second-day agenda for NASH-TAG 2021, with a diverse set of innovative and challenging topics. Louise Campbell, Ian Rowe, and Roger Green each identify a different discussion they will be most excited to hear. This is an animated conversation and good motivation to register for virtual NASH-TAG at ht...
27 Feb 202113min
S2-E8.1 - Previewing NASH-TAG 2021: Day One
Send us a text Stephen Harrison discusses the history of NASH-TAG and what makes it special while previewing Day One of the 2021 meeting. In this conversation, Stephen Harrison and Roger Green share their views of what makes NASH-TAG a special event, after which Stephen reviews the Day One agenda, focusing on elements he considers particularly exciting. Louise Campbell and Ian Rowe share what they value most from their own, unique perspectives. This is a great conversation, and excellent mo...
27 Feb 202117min
S2-E8 - Previewing NASH-TAG 2021
Send us a text Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12. This year marks the 5th annual NASH-TAG, a meeting focused solely on NASH drug and diagnostics development. The NASH-TAG format calls for "deep dives" into key issues and combines innovative presentation formats with debates on pivotal issues. Stephen Harrison walks Louise, Roger, and our guest Ian Rowe through the agenda. The panelists raise provoca...
25 Feb 202154min
S2-E7.3 - The newer diabetes drugs and NASH: Educating and Motivating Stakeholders
Send us a text The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success. Louise Campbell and Roger Green discuss issues and challenges in educating diabetic patients about NAFLD and NASH. Louise discusses how the rising amount of mortality tied to liver cancer should create a new urgency to broaden focus about the role the liver plays in metabolic health. Roger raises the role that reference labs like Quest and LabCorp have p...
20 Feb 202112min
S2-E7.2 - The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond
Send us a text Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes. Patient, patient advocate and Fatty Liver Foundation Wayne Eskridge considers ways that diabetic patients might respond to the joint ideas that they have fatty liver issues and that some diabetes drugs might treat them. He considers issues of information overload and education and the pivotal role phys...
20 Feb 202113min
S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action
Send us a text Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH. The group considers scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode-of-action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points an...
20 Feb 202116min
